Tech Company Financing Transactions
Generation Bio Funding Round
Generation Bio secured a $100 million Series B funding round on 2/28/2018. Investors included Fidelity Management & Research Company, Casdin Capital and Deerfield Capital.
Transaction Overview
Company Name
Announced On
2/28/2018
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds will be used to move Generation Bio's first two therapeutic candidates through Investigational New Drug (IND) enabling studies and to advance additional programs targeting genetic diseases of the retina, central nervous system and lungs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
301 Binney St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Generation Bio is creating a breakthrough class of genetic medicines that deliver durable, high levels of gene expression and can be re-dosed to titrate and sustain effect.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Geoff Mcdonough
Chief Financial Officer
Thomas Graney
Chief Operating Officer
Mark Angelino
Chief Scientific Officer
Matthew Stanton
VP - Bus. Development
Douglas Kerr
VP - Bus. Development
William McCarthy
VP - General Counsel
Jennifer Elliott
VP - Human Resources
Sara Besten
VP - Human Resources
Antoinette Paone
Browse more venture capital transactions:
Prev: 2/28/2018: AdHive venture capital transaction
Next: 2/28/2018: Hero Token venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record funding rounds that are announced publicly. VC transactions reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs